Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.43 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8304911 | 0.88 | GPR119 (0.47) | MAPTKDM4ETHRBHPGDGPR119 | |
| SCHEMBL23979945 | 0.85 | ALDH1A1 (0.45) | MAPTKDM4ETHRBHPGDGPR119 | |
| SCHEMBL4722920 | 0.85 | HPGD (0.47) | MAPTKDM4ETHRBHPGDGPR119 | |
| SCHEMBL27736427 | 0.84 | NR1H2 (0.42) | MAPTKDM4ETHRBHPGDGPR119 | |
| SCHEMBL1006353 | 0.84 | KDM4E (0.43) | MAPTKDM4ETHRBHPGDGPR119 | |
| SCHEMBL3114371 | 0.84 | KDM4E (0.43) | MAPTKDM4ETHRBHPGDGPR119 | |
| SCHEMBL19073726 | 0.82 | MEN1 (0.45) | MAPTKDM4ETHRBHPGDGPR119 | |
| SCHEMBL652243 | 0.82 | MEN1 (0.45) | MAPTKDM4ETHRBHPGDGPR119 | |
| SCHEMBL13047176 | 0.82 | MAPT (0.41) | MAPTKDM4ETHRBHPGDGPR119 | |
| SCHEMBL5765921 | 0.81 | MAPT (0.48) | MAPTKDM4ETHRBHPGDGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3877388-B1 | 5-[6-[[3-(4,5,6,7-TETRAHYDROPYRAZOLO[4,3-C]PYRIDIN-1-YL)AZETIDIN-1-YL]METHYL]MORPHOLIN-4-YL]QUINOLINE-8-CARBONITRILE DERIVATIVES AND SIMILAR COMPOUNDS AS TLR7-9 ANTAGONISTS FOR TREATING SYSTEMIC LUPUS ERYTHEMATOSUS | HOFFMANN LA ROCHE (CH) | 2023-07-26 | — | — | EP | disclosed |
| EP-3877388-B1 | 5-[6-[[3-(4,5,6,7-TETRAHYDROPYRAZOLO[4,3-C]PYRIDIN-1-YL)AZETIDIN-1-YL]METHYL]MORPHOLIN-4-YL]QUINOLINE-8-CARBONITRILE DERIVATIVES AND SIMILAR COMPOUNDS AS TLR7-9 ANTAGONISTS FOR TREATING SYSTEMIC LUPUS ERYTHEMATOSUS | HOFFMANN LA ROCHE (CH) | 2023-07-26 | — | — | EP | disclosed |
| US-20210300924-A1 | 5-[6-[[3-(4,5,6,7-TETRAHYDROPYRAZOLO[4,3-C]PYRIDIN-1-YL)AZETIDIN-1-YL]METHYL]MORPHOLIN-4-YL]QUINOLINE-8-CARBONITRILE DERIVATIVES AND SIMILAR COMPOUNDS AS TLR7-9 ANTAGONISTS FOR TREATING SYSTEMIC LUPUS ERYTHEMATOSUS | HOFFMANN-LA ROCHE INC. (US) | 2021-09-30 | — | — | US | disclosed |
| EP-3877388-A1 | 5-[6-[[3-(4,5,6,7-TETRAHYDROPYRAZOLO[4,3-C]PYRIDIN-1-YL)AZETIDIN-1-YL]METHYL]MORPHOLIN-4-YL]QUINOLINE-8-CARBONITRILE DERIVATIVES AND SIMILAR COMPOUNDS AS TLR7-9 ANTAGONISTS FOR TREATING SYSTEMIC LUPUS ERYTHEMATOSUS | F. Hoffmann-La Roche AG (CH) | 2021-09-15 | — | — | EP | disclosed |
| US-20170197960-A1 | ATX MODULATING AGENTS | BIOGEN MA INC. | 2017-07-13 | — | — | US | disclosed |
| US-8211926-B2 | Bicyclic pyrazolo-heterocycles | CARA THERAPEUTICS, INC. (US) | 2012-07-03 | — | — | US | disclosed |
| US-20110275609-A1 | BICYCLIC PYRAZOLO-HETEROCYCLES | CARA THERAPEUTICS, INC. (US) | 2011-11-10 | — | — | US | disclosed |
| US-20110144121-A1 | BICYCLIC PYRAZOLO-HETEROCYCLES | CARA THERAPEUTICS, INC. (US) | 2011-06-16 | — | — | US | disclosed |
| US-7741350-B1 | Bicyclic pyrazolo-heterocycles | CARA THERAPEUTICS, INC. (US) | 2010-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210300924-A1 | 5-[6-[[3-(4,5,6,7-TETRAHYDROPYRAZOLO[4,3-C]PYRIDIN-1-YL)AZETIDIN-1-YL]METHYL]MORPHOLIN-4-YL]QUINOLINE-8-CARBONITRILE DERIVATIVES AND SIMILAR COMPOUNDS AS TLR7-9 ANTAGONISTS FOR TREATING SYSTEMIC LUPUS ERYTHEMATOSUS | TLR7, TLR9, TLR8 | MAPT 4841/4885KDM4E 572/4885THRB 2679/4885 |
| US-20170197960-A1 | ATX MODULATING AGENTS | ENPP2, ATXN10, ATXN2 | MAPT 1228/4885KDM4E 2571/4885THRB 1308/4885 |
| US-20110144121-A1 | BICYCLIC PYRAZOLO-HETEROCYCLES | CNR1, CNR2, TRPV1 | MAPT 1923/4885KDM4E 3689/4885THRB 2009/4885 |
| US-20110275609-A1 | BICYCLIC PYRAZOLO-HETEROCYCLES | CNR1, CNR2, HRH4 | MAPT 1876/4885KDM4E 3336/4885THRB 1188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.